Nurix Therapeutics reports Vestal Point Capital and Ryan Wilder collectively hold 6,500,000 shares of Common Stock. The filing states this equals 6.3% of outstanding common stock, based on 103,405,813 shares outstanding as of March 20, 2026. Vestal Point Capital, LP is listed as the investment manager for the fund and account holding the shares; Mr. Wilder is disclosed as CIO and Managing Partner and signs the joint filing agreement.
Positive
None.
Negative
None.
Insights
Holding represents a single institutional stake equal to 6.3% of outstanding shares.
The Schedule 13G lists 6,500,000 shares held by the Vestal Point Fund and Account, representing 6.3% of the company's 103,405,813 shares outstanding as of March 20, 2026. This is a significant passive stake disclosure under beneficial ownership rules.
Future filings may show changes; the filing frames the position as held by the fund with Mr. Wilder signing in his managerial capacity.
Filing follows passive investor disclosure conventions under Schedule 13G.
The document identifies the reporting persons, their address, and voting/dispositive powers (shared voting/dispositive power of 6,500,000 shares). It references the company proxy for the outstanding share count used to calculate percentage.
Material qualifiers include the filing's statement that it should not be construed as an admission of beneficial ownership for Section 13 purposes; the signature block shows joint filing agreement executed on 05/15/2026.
Key Figures
Shares held:6,500,000 sharesPercent of class:6.3%Shares outstanding:103,405,813 shares+1 more
4 metrics
Shares held6,500,000 sharesVestal Point Fund and Account reported holding these shares
Percent of class6.3%Calculated using outstanding shares as of <date>March 20, 2026</date>
Shares outstanding103,405,813 sharesCompany Definitive Proxy Statement as of <date>March 20, 2026</date>
Filing date / signature05/15/2026Joint filing agreement and signatures executed
Key Terms
Schedule 13G, Beneficially owned, Shared Dispositive Power
3 terms
Schedule 13Gregulatory
"This statement is filed by: Vestal Point Capital, LP (the "Investment Manager")"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Beneficially ownedfinancial
"Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared Dispositive Powerfinancial
"Shared Dispositive Power 6,500,000.00"
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Nurix Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
67080M103
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
67080M103
1
Names of Reporting Persons
Vestal Point Capital, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,500,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,500,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,500,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.3 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
67080M103
1
Names of Reporting Persons
Ryan Wilder
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,500,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,500,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,500,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.3 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Nurix Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
1600 Sierra Point Parkway, Brisbane, California 94005
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) Vestal Point Capital, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to a certain fund and a managed account (the "Vestal Point Fund and Account"), with respect to the shares of common stock, par value $0.001 per share (the "Common Stock"), of Nurix Therapeutics, Inc. (the "Company") directly held by the Vestal Point Fund and Account; and
(ii) Mr. Ryan Wilder ("Mr. Wilder"), the Chief Investment Officer and Managing Partner of the Investment Manager and the Managing Member of Vestal Point Capital, LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Vestal Point Fund and Account.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the business office of each of the Reporting Persons is 632 Broadway, Suite 602, New York, NY 10012.
(c)
Citizenship:
The Investment Manager is a Delaware limited partnership. Mr. Wilder is a citizen of the United States.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP Number(s):
67080M103
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 103,405,813 shares of Common Stock outstanding as of March 20, 2026, as reported in the Company's Definitive Proxy Statement on Form DEF14A, filed with the Securities and Exchange Commission on March 27, 2026.
(b)
Percent of class:
6.3%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). The Vestal Point Fund and Account have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Vestal Point Capital, LP
Signature:
/s/ Ryan Wilder
Name/Title:
By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner
What stake does Vestal Point Capital report in Nurix Therapeutics (NRIX)?
Answer: Vestal Point reports holding 6,500,000 shares, equal to 6.3% of common stock. The percentage is calculated from 103,405,813 shares outstanding as of March 20, 2026, per the company's proxy statement.
Who are the reporting persons on the Schedule 13G for NRIX?
Answer: The filing is by Vestal Point Capital, LP (the investment manager) and Ryan Wilder (CIO and Managing Partner). Both signed a joint filing agreement dated 05/15/2026.
Does the Schedule 13G show Vestal Point has sole voting control of the shares?
Answer: No. The cover data shows 0 sole voting power and 6,500,000 shared voting power. Dispositive power is similarly shared, per the filing's cover-page rows.
What source was used to calculate the 6.3% ownership for NRIX?
Answer: The percentage is calculated using the 103,405,813 shares outstanding as of March 20, 2026, reported in the company's Definitive Proxy Statement on Form DEF14A filed March 27, 2026.
